Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Wang K, Huang X, Di Liberto M, Chen-Kiang S. Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy. Hematol Oncol Clin North Am. 2020;34(5):809-823.

Droesch C, Do MH, DeSancho M, Lee E-, Magro C, Harp J. Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19. JAMA Dermatol. 2020;156(9):1-3.

van der Mijn JC, Fu L, Khani F, Zhang T, Molina AM, Barbieri CE, et al. Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma. Transl Oncol. 2020;13(2):177-185.

Liu Y-, Margolskee E, Allan JN, Mathew S, Bhavsar E, Casano J, et al. Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis. Mod Pathol. 2020;33(3):344-353.

Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20(6):323-342.

Hayashi M, Guida E, Inokawa Y, Goldberg R, Reis LO, Ooki A, et al. GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma. Sci Signal. 2020;13(645).

Patel AP, Schatz-Siemers NF, Dilcher TL, Goyal A. The interpretation of high-grade squamous intraepithelial lesion on anal cytology: a comparative analysis with the cervical Papanicolaou test. J Am Soc Cytopathol. 2020;9(6):540-549.

Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, et al. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020;10(3):440-459.

Zhang S, Chiang GC, Knapp JM, Zecca CM, He D, Ramakrishna R, et al. Grading meningiomas utilizing multiparametric MRI with inclusion of susceptibility weighted imaging and quantitative susceptibility mapping. J Neuroradiol. 2020;47(4):272-277.

Basourakos SP, Awamlh BA, Bianco FJ, Patel NA, Laviana A, Margolis DJ, et al. Feasibility of in-office MRI-targeted partial gland cryoablation for prostate cancer: an IDEAL stage 2A study. BMJ Surg Interv Health Technol. 2020;2(1):e000056.